InstalabLoading...
InstalabLoading...
If you have had an unexplained blood clot, a stroke at a young age, or recurrent pregnancy losses, your doctor may have checked for antiphospholipid antibodies. But the standard panel only looks at two of the three antibody classes. Cardiolipin Antibody IgA (immunoglobulin A anticardiolipin) is the third class, and it can be the only one that comes back positive in a small but real subset of people with clotting problems.
This test measures whether your immune system is producing IgA antibodies that target cardiolipin, a fat molecule embedded in cell membranes. When these antibodies are present, they can push your blood toward clotting too easily, raising the risk of deep vein thrombosis, pulmonary embolism, stroke, heart attack, and pregnancy complications. The catch is that IgA is not yet part of the formal diagnostic criteria for antiphospholipid syndrome (APS), so it is often left off the order form. That means you could test "negative" on a standard panel and still have a meaningful autoimmune signal hiding in the IgA channel.
Anticardiolipin antibodies are autoantibodies, meaning they are immune proteins your own body produces against its own tissues. They belong to the immunoglobulin family and come in three classes: IgG, IgM, and IgA. Each class reflects a different arm of your immune response. IgG is generally the strongest predictor for blood clots and pregnancy problems. IgM captures a somewhat different risk profile. IgA is the least studied of the three but can identify patients the other two miss.
These antibodies target negatively charged fat molecules (phospholipids) on the surface of platelets and blood vessel walls. They often bind through a helper protein called beta-2 glycoprotein I. When they attach, they disrupt the normal balance between clotting and anti-clotting signals, tipping the system toward forming dangerous clots in arteries and veins.
Antiphospholipid antibodies, including the IgA class, are linked to both venous and arterial blood clots. In a study of 472 patients referred for unexplained clotting, IgA antiphospholipid antibodies were found to be an independent risk factor for thrombosis. A separate prospective study of 2,427 adults without prior cardiovascular disease found that positive IgA anticardiolipin and IgA anti-beta-2 glycoprotein I at a single time point were independently associated with future atherosclerotic cardiovascular events.
In 50-year-old men, raised antibodies against cardiolipin predicted heart attack and heart-attack-related death 10 to 20 years later. And in a large lupus cohort of 1,573 patients, positive antiphospholipid antibodies were associated with future cardiovascular disease, with aspirin appearing to reduce that risk. These findings suggest that even outside of classic APS, cardiolipin antibodies can signal an increased cardiovascular threat.
Antiphospholipid antibodies are one of the few treatable causes of recurrent pregnancy loss. In a study of 1,154 women with recurrent miscarriage, 17.3% had positive anticardiolipin antibodies. IgA anticardiolipin was highly prevalent in a group of 84 women with pregnancy complications, though it usually appeared alongside IgG or IgM rather than alone. Even low levels of anticardiolipin antibodies have been associated with a higher rate of pregnancy complications in a cohort of over 3,000 pregnancies, particularly when the IgG class was present.
The clinical value of IgA specifically for pregnancy risk is less clear than for IgG. In most studies, IgA anticardiolipin adds limited diagnostic information beyond what IgG and IgM already provide for obstetric APS. Its role is strongest when standard tests are negative but the clinical picture is convincing.
IgA anticardiolipin shows up in several autoimmune conditions beyond classic APS. In systemic lupus erythematosus (SLE, a condition in which the immune system attacks many different tissues), about 16% of patients in a Swedish cohort had IgA antiphospholipid antibodies. In autoimmune thyroid disease, antiphospholipid antibodies were more common than in healthy controls, with IgA being the predominant class. And in rheumatoid arthritis, IgA was the most common class of anti-beta-2 glycoprotein I antibody, correlating with levels of anti-CCP (a marker of more aggressive joint disease).
IgA anticardiolipin has also been associated with specific features in APS patients: a skin pattern called livedo reticularis (a lacy, purplish discoloration) and heart valve disease.
Current APS classification criteria use only IgG and IgM anticardiolipin, IgG and IgM anti-beta-2 glycoprotein I, and a functional clotting test called the lupus anticoagulant. IgA is considered a "non-criteria" marker. That label does not mean it is useless. It means the evidence is not yet strong enough, and assay standardization is not yet good enough, to include it in formal diagnostic frameworks.
In a large multicenter European study of 1,068 patients, adding IgA anticardiolipin and IgA anti-beta-2 glycoprotein I to the standard panel did not increase the odds ratios for thrombosis or pregnancy complications. Isolated IgA positivity (IgA positive but IgG and IgM negative) was rare, occurring in only about 0.3% to 5% of cases. A 7,293-person Chinese cohort reached a similar conclusion: IgA did not improve diagnostic performance and was rarely positive alone.
But that is the average picture. In a specific, narrower scenario, IgA matters: when a person has clear APS symptoms (clots, pregnancy losses) but tests negative on all standard criteria antibodies. This is called seronegative APS, and non-criteria antibodies including IgA anticardiolipin can unmask up to 60% of these patients. In one study, asymptomatic carriers of IgA anti-beta-2 glycoprotein I (a closely related marker) had a meaningfully higher 5-year risk of thrombotic events, particularly arterial clots.
There is no single universal cutoff for IgA anticardiolipin. Assays vary enormously between labs, and more than 90% of labs simply use whatever reference range their test kit manufacturer provides. In external quality surveys, different labs frequently disagree on whether the same sample is positive or negative, with measurements on the same sample differing by more than 50% from one lab to another for anticardiolipin testing in general.
The following ranges come from a prospective lupus study using an automated antibody detection method, with cutoffs derived from 400 healthy donors. They are illustrative, not universal targets. Your lab will likely report different numbers.
| Category | IgA aCL Level | What It Suggests |
|---|---|---|
| Negative | Below 14 U/mL | No detectable IgA anticardiolipin signal |
| Positive (manufacturer cutoff) | 14 U/mL or above | IgA anticardiolipin detected; clinical context determines significance |
| Positive (99th percentile of healthy donors) | 17 U/mL or above | Meets a stricter research threshold used in some APS studies |
Compare your results within the same lab over time for the most meaningful trend. Switching labs or assay platforms can make a result appear to change when it has not.
The biggest source of error with this test is not what you ate or how much you exercised. It is assay variability and specific biological interferences.
A single anticardiolipin result is never enough to draw conclusions. APS diagnosis requires that antibodies be confirmed on at least two separate occasions, typically 12 weeks apart, to prove they are persistent rather than a one-time blip from an infection or lab artifact. This is not a formality. Transient positivity after infections (including COVID-19) is common and does not carry the same clotting risk as persistent autoimmune positivity.
Within the lab, standardized antiphospholipid antibody assays show good analytical precision. In studies of anti-beta-2 glycoprotein I (a closely related test), repeat measurements on the same system varied by only about 2% to 7%, and multicenter studies of anticardiolipin on automated platforms show similarly strong within-center agreement. The problem is not your lab's repeatability. It is between-lab disagreement. If you switch labs or your lab changes assay platforms, your numbers may shift without any real change in your biology. Stick with the same lab and same assay when tracking over time.
If you are testing proactively, get a baseline, then retest in 12 weeks if positive. If negative and your clinical risk is low, annual monitoring is reasonable. If you are positive on two occasions 12 weeks apart, that persistent signal warrants further workup regardless of whether you have had symptoms.
If your IgA anticardiolipin comes back positive, the first step is confirming the result is real. Retest at the same lab in 12 weeks. If it is still positive, you need the rest of the antiphospholipid panel: IgG and IgM anticardiolipin, IgG and IgM anti-beta-2 glycoprotein I, and a lupus anticoagulant test. These are the formal criteria markers and will determine whether you meet the classification for APS.
If all standard criteria markers are negative but your IgA remains positive and you have had a clot or pregnancy loss, you may fall into the seronegative APS category. This is where a rheumatologist or hematologist with APS expertise becomes essential. Additional non-criteria antibodies (anti-phosphatidylserine/prothrombin, anti-domain I of beta-2 glycoprotein I) can help clarify the picture.
If you are positive but have never had a clot or pregnancy complication, the situation is less clear-cut. One study found that asymptomatic carriers of IgA anti-beta-2 glycoprotein I had a higher 5-year rate of thrombotic events, but this finding has not been consistently replicated. Discuss with a specialist whether low-dose aspirin or closer monitoring is appropriate for your situation.
Cardiolipin Antibody IgA is best interpreted alongside these tests.